Assessing and Communicating the Value of Biomedical Research: Results From a Pilot Study

Susan Guthrie1, Joachim Krapels, Alexandra Adams

  • 1S. Guthrie is research leader, RAND Europe, Cambridge, United Kingdom. J. Krapels is senior analyst, RAND Europe, Cambridge, United Kingdom; ORCID: http://orcid.org/0000-0003-0891-6083. A. Adams is director, Center for American Indian and Rural Health Equity, Montana State University, Bozeman, Montana. At the time of the research presented here, she served as director, Collaborative Center for Health Equity, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. P. Alberti is senior director, Health Equity Research and Policy, Association of American Medical Colleges, Washington, DC. A. Bonham is former chief scientific officer, Association of American Medical Colleges, Washington, DC. B. Garrod is senior analyst, RAND Europe, Cambridge, United Kingdom; ORCID: http://orcid.org/0000-0001-7634-2590. S. Esmond is administrative director, Collaborative Center for Health Equity, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. C. Scott is health equity outreach specialist, Collaborative Center for Health Equity, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. G. Cochrane is senior analyst, RAND Europe, Cambridge, United Kingdom. S. Wooding is lead for research and analysis, Centre for Science and Policy, University of Cambridge, Cambridge, United Kingdom; ORCID: http://orcid.org/0000-0002-8036-1054.

Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
268
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Statistical Significance01:50

Statistical Significance

Once data is collected from both the experimental and the control groups, a statistical analysis is conducted to find out if there are meaningful differences between the two groups. A statistical analysis determines how likely any difference found is due to chance (and thus not meaningful). In psychology, group differences are considered meaningful, or significant, if the odds that these differences occurred by chance alone are 5 percent or less. Stated another way, if we repeated this...
22.9K